Impact of response to thalidomide-, lenalidomide- or bortezomib-containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

被引：5

作者：

Awan, F. T. ^{[1
]}

Osman, S. ^{[2
]}

Kochuparambil, S. T. ^{[1
]}

Gibson, L. ^{[2
]}

Remick, S. C. ^{[2
]}

Abraham, J. ^{[2
]}

Craig, M. ^{[2
]}

Jillella, A. ^{[1
]}

Hamadani, M. ^{[2
]}

机构：

[1] Med Coll Georgia, Dept Internal Med, Div Hematol Oncol, Augusta, GA 30912 USA

[2] W Virginia Univ, MBRCC, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA

来源：

BONE MARROW TRANSPLANTATION | 2012年 / 47卷 / 01期

关键词：

BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; AUTOTRANSPLANTATION; CHEMOTHERAPY; TRIAL;

D O I：

10.1038/bmt.2011.18

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：146 / 148

页数：3

共 10 条

[1]

ALEXANIAN R, 1995, STEM CELLS, V13, P118

[2] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[3]

BARLOGIE B, 1987, BLOOD, V70, P869

[4] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[5] Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction [J].

Gertz, Morie A. ;

Kumar, Shaji ;

Lacy, Martha Q. ;

Dispenzieri, Angela ;

Dingli, David ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Hogan, William J. .

BLOOD, 2010, 115 (12) :2348-2353

[6] Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone [J].

Harousseau, Jean-Luc ;

Palumbo, Antonio ;

Richardson, Paul G. ;

Schlag, Rudolf ;

Dimopoulos, Meletios A. ;

Shpilberg, Ofer ;

Kropff, Martin ;

Kentos, Alain ;

Cavo, Michele ;

Golenkov, Anatoly ;

Komarnicki, Mieczyslaw ;

Mateos, Maria-Victoria ;

Esseltine, Dixie-Lee ;

Cakana, Andrew ;

Liu, Kevin ;

Deraedt, William ;

van de Velde, Helgi ;

San Miguel, Jesus F. .

BLOOD, 2010, 116 (19) :3743-3750

[7] High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy [J].

Kumar, S ;

Lacy, MQ ;

Dispenzieri, A ;

Rajkumar, SV ;

Fonseca, R ;

Geyer, S ;

Allmer, C ;

Witzig, TE ;

Lust, JA ;

Greipp, PR ;

Kyle, RA ;

Litzow, MR ;

Gertz, MA .

BONE MARROW TRANSPLANTATION, 2004, 34 (02) :161-167

[8]

Moreau P, 2010, BLOOD

[9] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma [J].

Singhal, S ;

Powles, R ;

Sirohi, B ;

Treleaven, J ;

Kulkarni, S ;

Mehta, J .

BONE MARROW TRANSPLANTATION, 2002, 30 (10) :673-679

[10] High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a southwest oncology group phase II trial [J].

Vesole, DH ;

Crowley, JJ ;

Catchatourian, R ;

Stiff, PJ ;

Johnson, DB ;

Cromer, J ;

Salmon, SE ;

Barlogie, B .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2173-2179

← 1 →